Articles related to ENDOMETRIAL CANCER

The FDA has approved a combination therapy of pembrolizumab, carboplatin, and paclitaxel for advanced endometrial cancer, significantly enhancing progression-free survival rates for patients with both mismatch repair deficient and proficient statuses.

In this study, dostarlimab combined with carboplatin-paclitaxel demonstrated a marked improvement in progression-free and overall survival among endometrial cancer patients, particularly those with genetic markers for dMMR and MSI-H.

Selinexor has demonstrated an extraordinary extension in progression-free survival in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to the recent findings from the SIENDO study.

According to earlier studies, the usage of some hair products, such as relaxers and pressing products, may raise the risk of ovarian cancer. The usage of hair straighteners may now also be related to uterine cancer, according to a recent study. The CDC lists using birth control pills, working out frequently, maintaining a healthy weight, and taking progesterone as required as factors that lower the risk of uterine cancer.

Results from the RUBY trial of dostarlimab and the GY018/Keynote-068 of pembrolizumab were presented at the 2023 SGO Annual Meeting on Women’s Cancer in March and were simultaneously published in The New England Journal of Medicine. The studies examined the efficacy and safety of the medications in all individuals and those with mismatch repair deficient (dMMR) illness. Each trial examined a separate PD-1 inhibitor, pembrolizumab or dostarlimab, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer. In individuals with dMMR illness, both medications lowered the chance of disease progression or death by roughly 70%.